chemotherapy-induced nausea and vomiting
Conditions
Interventions
Sponsors
Shanghai General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Histologically or cytologically confirmed malignant gastrointestinal solid tumors; 2.Currently receiving anti-tumor therapy; 3.Planned to receive Fosrolapitant and Palonosetron Hydrochloride for Injection treatment; 4.Aged 18 years or older; 5.Informed consent obtained;
Exclusion criteria
Exclusion criteria: 1.Patients with hypersensitivity to the study drug or its excipients; 2.Tumor patients with gastrointestinal obstruction, increased intracranial pressure, or other primary diseases that can cause nausea and vomiting;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete response during the overall phase of the first antitumour treatment cycle; | — |
Secondary
| Measure | Time frame |
|---|---|
| Complete response during the acute phase, the delayed phase, >120-168 hours after each cycle of antineoplastic therapy;Overall efficacy rate and proportion of rescue medication during the acute phase, the delayed phase, 0-120 hours, >120-168 hours after each cycle of antineoplastic therapy; | — |
Countries
China
Contacts
Public ContactHao Chen
Shanghai General Hospital
Outcome results
None listed